TrialsgrambetaRCTs are beautiful

DUPLEX

2023

Sparsentan in Focal Segmental Glomerulosclerosis

In 371 patients with focal segmental glomerulosclerosis, sparsentan reduced proteinuria but did not significantly improve eGFR slope compared with irbesartan.

Result

Primary endpoint: eGFR slope over 108 weeks

Total-slope difference +0.3 mL/min/1.73m²/yr (95% CI −1.7 to 2.4; primary eGFR-slope endpoint missed); FSGS partial remission 42.0% vs 26.0% (p=0.009).

Original publication
Subtopic
FSGS
Design
Phase 3 active-controlled RCT
Relevance
Supporting: context rather than must-know.
Source
Rheault MN, et al. N Engl J Med. 2023;389(26):2436-2445.doi 10.1056/NEJMoa2308550

Discussion & critique

A clean example of proteinuria reduction without an eGFR-slope benefit; no FSGS approval, unlike for IgA nephropathy.

Discussed in podcasts